Objective Women who have delivered a smallfor-gestational-age (SGA) 
INTRODUCTION
Endothelial-dependent flow-mediated dilation (FMD) is a non-invasive method of assessing vascular function 1 . By measuring the change in brachial artery diameter in response to increased blood flow, endothelial function can be assessed at the same time 2 . Women who have experienced pre-eclampsia are at increased risk of cardiovascular disease (CVD) 3 . Subclinical maternal endothelial dysfunction is evident within 6 months of delivery of a pregnancy affected by pre-eclampsia, as shown by a lower FMD 4 . Women who have had a baby in the lowest birth-weight quintile for gestational age, as well as those who have delivered a small-for-gestational-age (SGA) infant (independent of other recognized risk factors), have an increased lifetime risk of ischemic heart disease (IHD) 5 . This risk is dose dependent, varying according to the severity of the SGA and the number of previous SGA pregnancies 6 . It is less clear whether early impaired endothelial dysfunction is present in women who have delivered a SGA or growth-restricted infant.
As pregnancy progresses, high-resistance maternal uterine arteries are transformed into low-resistance, high capacitance vessels to facilitate the provision of oxygen and nutrients for placental development and optimal fetal growth. Dysfunction within the placenta is thought to be a central component of both pre-eclampsia and fetal growth restriction (FGR) 7 . It is possible that aberrant remodeling of the uteroplacental circulation resulting in a growth-restricted fetus might be influenced by the underlying maternal vascular phenotype or, conversely, compromised placental development may itself influence future maternal vascular health.
Given that subclinical endothelial dysfunction is a prelude to the later development of CVD 8, 9 , and brachial artery FMD is correlated inversely with future cardiovascular events 10 , then identification, using FMD, of women with postpartum subclinical endothelial dysfunction would provide a novel way of identifying those at future risk of CVD. This could therefore have the potential to prevent or ameliorate disease in these women through personalized lifestyle adjustments and monitoring.
In this study we sought to investigate endothelial function in women who had a pregnancy complicated by SGA, independent of other maternal and fetal diseases. We hypothesized that impaired endothelial function would be evident shortly after the affected pregnancy, similar to that seen in cases of pre-eclampsia.
METHODS
This was a case-control study undertaken at the Clinical Research Facility, University College London Hospital (UCLH). Ethical approval for this study was granted by the Joint UCLH/UCL (alpha) Ethical Committee (09/H0715/28). Expectant couples were recruited prenatally over a 15-month period, giving them sufficient time to consider the study and to consent to the collection of fetal samples after delivery. Eligible participants were approached in a range of hospital settings, as described in our previous publication 11 . Pregnant women with a growth-restricted fetus were recruited as study cases. SGA was identified by prenatal ultrasound and was defined as a customized birth weight of < 10 th centile 12 . All cases of SGA were confirmed by postpartum measurements. Pregnant women with an appropriately grown fetus, defined as one with an estimated fetal weight between the 10 th and 95 th customized centiles on prenatal ultrasound and confirmed by postnatal assessment, were recruited as controls during the same study period and from the same clinical area as were the cases. Pregnancies affected by a fetal anomaly were excluded, as were women who smoked and women who developed pre-eclampsia or had gestational hypertension (blood pressure > 140/90 mmHg), in order to best elicit placentally derived growth restriction, independent of the effect of pre-eclampsia, and to minimize the confounding influences of extrinsic maternal factors. Each parent completed a questionnaire about past medical, family and treatment histories. Birth weight was remembered personally or was provided by their parent. Maternal antenatal notes were reviewed to provide pertinent data.
Women were invited back by letter, e-mail or telephone call for postpartum evaluation between 4 months and 1 year after childbirth, after breastfeeding had ceased and on a day when the participant would not be menstruating. The study room was temperature controlled at 24
• C.
Participants were asked to fast overnight for at least 10 h before assessment and all postnatal assessments were performed in the morning. Maternal weight, height and abdominal circumference were recorded. After resting, two measurements of supine blood pressure were taken, 15 min apart. The same trained operator measured blood pressure by auscultatory sphygmomanometry, using an aneroid sphygmomanometer, with the participant in a sitting position. Where appropriate, cuff sizes were adjusted to arm circumference. The mean value of two separate measurements obtained 15 min apart was used for analysis. Fasting venous insulin, glucose and lipid levels were measured. Insulin resistance was calculated using the homeostasis model assessment (HOMA) method 13 . Blood samples were spun within 1 h of venepuncture and the plasma and serum were frozen at −80
• C. All blood samples were processed in the same laboratory. Endothelial function was assessed by brachial artery FMD. A single operator, trained and validated within an established group using FMD, performed the scans, using established protocols as reported previously 14 . Briefly, the right arm was rested in an arm holder and the forearm was raised slightly using a foam pad. An 8.5-cm wide pneumatic cuff was placed around the upper forearm, 2 cm distal to the medial epicondyle ( Figure 1 ). Cuff pressure inflation was controlled by an automatic cuff inflator (Hokanson Cuff Inflator, PMS Instruments Ltd, Maidenhead, UK). Using an Aloka SSD 5000 ultrasound machine (Aloka Holding Europe, AG Switzerland) with a 13-MHz linear array transducer probe in the longitudinal plane, a segment of the brachial artery was identified and studied before and after 5 min of compressive arterial occlusion. The image was acquired in B-mode and the probe was fixed so that a 5-10-cm segment of the brachial artery proximal to the antecubital fossa was in view. Longitudinal end-diastolic images, in conjunction with electrocardiogram tracing, were acquired every 3 s during the 11-min recording (1 min baseline, 5 min with cuff inflation at 300 mmHg and 5 min with cuff deflated). Blood flow velocity was monitored continuously during the examination by switching to a B/D (Doppler) mode for the duration of the test.
Images were acquired and analyzed using automated software (Brachial Tools Medical Imaging Applications, IA, USA). With the initial segment recorded, a smaller region with maximum clarity was selected for analysis. To provide internal reproducibility, two different segments within each scan were analyzed and compared for similarity. Stringent inclusion criteria were applied. If the image was of poor quality the recording was deemed to be unrepresentative of the true vessel diameter, and if the image did not return to near baseline after reperfusion, the image was excluded from analysis. Each image recording was validated by a second operator, blinded to the subject's allocated group of SGA or appropriately grown for gestational age (AGA). FMD was calculated as a percentage change from baseline brachial artery diameter (mm) to maximum dilation (mm) after reperfusion, using semiautomated continuous capture software. Scans were excluded if the FMD obtained from two different segments or from second-operator validation differed by > 1.5%.
Statistical analysis
Cases and controls were assessed for comparability with simple descriptive statistics. Baseline prenatal characteristics and postnatal measurements of cases and controls are summarized as mean ± SD for continuous variables and as percentages for categorical variables. Statistical analysis was carried out using STATA 10 (StataCorp LP, TX, USA) and GraphPad Prism version 5 (GraphPad Software Inc., CA, USA). Normality of data was determined by visual assessment of their distribution. Data were compared using the unpaired t-test. Two-tailed P of < 0.05 was considered to be statistically significant.
RESULTS
Recruitment of expectant women into the study was carried out over a 15-month period. Women were invited back for postpartum assessment by telephone call, e-mail or letter. In eight cases no response was received or the woman's details were out of date. Of the 94 women contacted, 61 (65%) were assessed in the postnatal period. Of the 33 women not assessed, eight were pregnant at the time of recall, 10 declined to return for assessment having moved area or were initially out of the area and 15 declined owing to work or family commitments.
In total, 24 women who had a pregnancy affected by SGA (cases) and 37 women who delivered an AGA neonate (controls) were able to attend postnatal appointments. Of the SGA cases, four women also experienced pre-eclampsia and were excluded from the final analysis. After performing quality checks of the FMD recordings (as described in the Methods section), eight controls and five cases were excluded: the second-operator validation FMD value differed from the first-operator measurement by > 1.5% in four women (two cases and Data are given as mean ± SD (range), n (%) or mean ± SD. SGA defined as birth weight < 10 th customized centile. AGA defined as birth weight within 10-95 th customized centiles. BMI, body mass index; BP, blood pressure. two controls); the FMD did not return to baseline by the end of the recording in five women (two cases and three controls); the recording was not completed in two controls; and image quality was poor in two women (one case and one control). Thus, 29 recordings of postnatal FMD in mothers with AGA offspring and 15 in mothers with SGA offspring were eligible for analysis.
Baseline characteristics of the 44 infants born to the participants confirmed that case and control offspring subjects met the study criteria. In cases, the mean customized birth-weight centile was 1.9 ± 2.3, with a mean birth weight of 2254 ± 547 g and a gestational age at delivery of 268 ± 19.4 days. In controls, the mean customized birth-weight centile was 47.5 ± 26.3, with a mean birth weight of 3566 ± 350 g and a gestational age at delivery of 285 ± 9.6 days.
There were no differences in maternal age, weight, height and parity at the time of study enrollment during early pregnancy between cases and controls (Table 1) . There was no difference in blood pressure at 10-12 weeks' gestation between the two groups and no women in either group developed sustained hypertension > 140/90 mmHg before childbirth or peripartum. Maternal blood pressure at the time of postpartum FMD evaluation remained similar between the groups (Table 2) . Prenatally and peripartum, no woman had prepregnancy hypertension or any significant medical condition.
Postnatal assessment was carried out 6.9 ± 2.5 months postpartum in mothers with an AGA offspring and 6.8 ± 2.5 months postpartum in mothers with a SGA offspring (95% CI for intergroup difference, −1.537 to 1.690; P = 0.92). Postpartum, there were no differences between cases and controls with regard to maternal weight, abdominal circumference or blood pressure (Table 2 ). More women in the SGA group had a Cesarean section (67%) than did women in the AGA group (28%). Women whose pregnancy had been complicated by SGA had lower FMD than did women who had an appropriately grown baby (6.79 ± 0.95% vs 10.26% ± 2.44% (95% CI for intergroup difference, −5.37 to −1.57); P = 0.0007). Postpartum fasting glucose and insulin levels were similar between controls and cases, which reflected no difference in insulin resistance, as defined by the HOMA insulin resistance index. There were also no differences in lipid profile, renal function, 25-hydroxyvitamin D and vitamin B12 or folate levels between cases and controls.
DISCUSSION

Principal findings
In healthy individuals, FMD is reported to range from 8-15%
2 . The data generated from this study support the concept that impaired endothelial function is present postnatally in women who have had a pregnancy affected by SGA. Importantly, these pregnancies were ones felt to have been affected by impaired placental function, reflecting a pathological in-utero growth pattern. Growth restriction, like pre-eclampsia, might act as a maternal 'stressor', triggering a pre-existing underlying maternal vascular phenotype.
To avoid the influence of known risk factors for endothelial dysfunction, women who had chronic disease, pre-eclampsia or smoked and mothers who were still breastfeeding were excluded from the analysis. Despite this, it is possible that compromised placental development may itself influence future maternal vascular health.
Comparison with findings of previous studies
Maternal endothelial dysfunction is known to be impaired during and after a pregnancy complicated by pre-eclampsia 15, 16 . We found similar FMD measurements in mothers who had a pregnancy affected by SGA to those found in mothers after a pregnancy affected by pre-eclampsia (7.3 ± 2.4%) 16 . Large-scale retrospective population studies have shown that women who have had an SGA baby have an increased risk of IHD 5, 6, 17 . It has been reported that women who have a pregnancy affected by growth restriction exhibit within 4 years worse endothelial function and metabolic profiles than does a control population 18, 19 . However, one study found that maternal blood pressure was higher during pregnancy and the postpartum study period in those affected by SGA than in women who had AGA offspring. In our study, maternal blood pressure was similar at the time of booking and during labor between SGA and AGA pregnancies (data not shown).
Women in our study with a growth-restricted pregnancy were asymptomatic without marked metabolic dysfunction, yet they had subclinical endothelial dysfunction, a recognized prelude to metabolic syndrome and CVD, soon after delivery. A meta-analysis of 14 prospective studies revealed that the risk of a cardiovascular event is reduced by 13% for every 1% increase in FMD 20 .
Limitations
We included cases of SGA whose phenotype was well defined, however the postnatal evaluation was carried out 6 months after initial recruitment, with stringent exclusion criteria. A limitation of this study was the loss to follow up (∼40%) of participants recruited prenatally. However, when analyzed, drop-out rates and the reasons for non-attendance were similar in both groups, probably limiting any bias effect. We found that FMD in women who had a pregnancy with SGA was 3.47 percentage points lower than in women who had an AGA infant. Although this value could represent a meaningful difference in cardiovascular risk between the groups, it is possible that the association between FMD and CVD is not as strong in asymptomatic populations 21 . Owing to stringent exclusion criteria, a number of FMD recordings were excluded from the analysis. The number excluded due to second-operator disagreement was only ∼6%, which is consistent with previously published data 22 , however the overall number of women excluded owing to additional criteria was higher. Given the number of exclusions, caution should be exercised when interpreting the results. However, a subanalysis of the rejected images and pre-eclamptic subjects did not alter the overall finding of lower FMD in cases than in controls. FMD can vary according to a number of environmental factors such as the time of day, prior food consumption and phase of the menstrual cycle 1 . While we tried to account for these factors, they may be confounding the results. A larger longitudinal cohort study, replicating these initial results, would strengthen the association identified and has been planned as part of a follow-on study.
Implications for practice
The pathophysiological pathway by which poor placental function with SGA, in the absence of gestational hypertension/pre-eclampsia, is associated with maternal endothelial dysfunction is yet to be elucidated. A prospective study of pregnancy outcomes with preconception and postnatal measurement of maternal FMD in the same women would elucidate the role of pregnancy-induced endothelial dysfunction. Reproducibility of the technique, as evidenced in this study, along with its high operator dependency are issues that need to be taken into account for future study designs or if implementation in a clinical setting is considered. Longitudinal follow-up could also elicit whether decreased FMD persists in these individuals, as there is some evidence to suggest that the changes in FMD resolve after 10 years 23, 24 . 
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